Molecular and immune profiling of HER2-low, HER2 ultra-low, and HER2-null male breast cancer.
Male breast cancer patients show distinct molecular features that might make them suitable for new antibody therapies approved for female breast cancer, potentially expanding treatment options.
This study provides the first molecular and immune profiling of male breast cancer stratified by HER2-low, ultra-low, and null categories, an important distinction given T-DXd's approval in HER2-low female breast cancer but lack of data in male breast cancer. The findings characterize whether male breast cancer patients may benefit from HER2-targeted ADC therapy and identify unique immunologic features that could inform treatment planning in this understudied, underserved population.
What the study was
- Study design
- Retrospective molecular profiling cohort study
- Population
- Male breast cancer patients with molecular profiling stratified by HER2-low, HER2 ultra-low, and HER2-null categories
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Breast (Edinburgh, Scotland)
Why it surfaced
Fills critical gap in HER2-low/ultra-low characterization for male breast cancer—an underserved, understudied group excluded from most T-DXd trials—with direct implications for precision therapy eligibility. Classification confidence medium; abstract not efetched.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.